Illustrative photo Boehringer Ingelheim Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast ...

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, were approximately $8 million. Mustang intends to use the net ...

Radiopharm Theranostics Ltd (ASX:RAD), a company specializing in pharmaceutical preparations with a market capitalization of $36.51 million, reported today that its latest clinical trial data ...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gros ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Cybin Inc. (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative ...